RSV Testing Not Recommended in Children Over 5 Years
Routine RSV testing is not recommended in children older than 5 years because RSV rarely causes clinically significant disease requiring specific management in this age group, and identifying the viral etiology does not change clinical management or outcomes.
The Core Rationale
The fundamental issue is that at the individual patient level, identifying RSV as the specific viral etiology has not been demonstrated to have clinical value 1. This principle applies even more strongly to older children than to infants and young children where RSV testing is already discouraged.
Age-Related Disease Burden
RSV disease burden is heavily concentrated in specific populations:
- Infants under 1 year experience the highest burden, with bronchiolitis hospitalizing 24.2 per 1000 infants annually 2
- RSV accounts for 60-75% of bronchiolitis cases in hospitalized infants 1
- By age 5 years and beyond, RSV typically causes mild upper respiratory symptoms indistinguishable from other viral infections
- The severe lower respiratory tract infections that characterize RSV in infancy become exceedingly rare in immunocompetent children over 5 years
Management is Supportive Regardless of Etiology
Treatment of RSV infection is mainly supportive, with no RSV-specific antivirals available for routine use in children 3, 4. This means:
- Bronchodilators are not recommended 1
- Corticosteroids are not useful 4
- Antibiotics do not treat viral infections 4
- Supportive care (hydration, oxygen if needed) is the same whether RSV or another virus is the cause
Testing Priority Framework
When respiratory virus testing is considered in children with severe illness, testing should prioritize influenza and COVID-19, as there are specific antiviral drugs for these diseases 3. This represents a more rational use of diagnostic resources since positive results would actually change management.
Clinical Decision-Making Without Testing
The 2014 American Academy of Pediatrics guideline emphasizes that bronchiolitis remains a clinical diagnosis, and diagnostic testing is not routinely recommended 4. This applies to the younger, higher-risk population where RSV is most prevalent—making it even less justified in children over 5 years.
The Only Exception
The sole clinical scenario where RSV testing is recommended is when an infant receiving monthly palivizumab prophylaxis is hospitalized with bronchiolitis 1. If breakthrough RSV infection is confirmed, prophylaxis should be discontinued due to the very low likelihood of a second RSV infection in the same year. This exception does not apply to children over 5 years, who are not candidates for palivizumab.
Practical Implications
Testing heterogeneity across healthcare settings demonstrates that even in high-risk populations, not all children with lower respiratory tract infections are tested for RSV 5. In children over 5 years:
- The pre-test probability of clinically significant RSV disease is extremely low
- The post-test management remains unchanged
- Resources are better allocated to testing for pathogens with specific treatments
- PCR assays may detect prolonged viral shedding from previous illness, particularly with rhinovirus, leading to false attribution of current symptoms 1
Infection Control Caveat
The one non-clinical reason to consider RSV testing in any age group would be for infection control purposes in healthcare settings—to implement appropriate isolation precautions and prevent nosocomial transmission. However, this is an institutional decision based on cohorting needs, not a routine clinical recommendation for individual patient management.